Evidence map›Paper›PMID 39949931›Full record

ArticleAmerican journal of cancer research2025

Retinoic acid receptor-β deletion in a model of early pancreatic ductal adenocarcinoma (PDAC) tumorigenesis.

Eduardo Mere Del Aguila, Xiao-Han Tang, Lorraine J Gudas

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eduardo Mere Del AguilaDepartment of Pharmacology and Meyer Cancer Center, Weill Cornell Medicine 1300 York Avenue, New York, NY 10065, USA.
Xiao-Han TangDepartment of Pharmacology and Meyer Cancer Center, Weill Cornell Medicine 1300 York Avenue, New York, NY 10065, USA.
Lorraine J GudasDepartment of Pharmacology and Meyer Cancer Center, Weill Cornell Medicine 1300 York Avenue, New York, NY 10065, USA.

Funding

CANCER PHARMACOLOGYT32CA062948 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LORRAINE J GUDAS · 1994 to 2026
$12.1M
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal CancersR01CA205258 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2016 to 2020
$2.5M
CD 1530, an RAR Gamma Agonist for Oral Cavity Squamous Cell Carcinoma PreventionR01CA270248 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LORRAINE J GUDAS · 2023 to 2026
$1.8M
NCI NIH HHS R01 CA205258NCI NIH HHS R01 CA270248NCI NIH HHS T32 CA062948
6 · The paper itself

Abstract

Vitamin A (VA, retinol) and its metabolites, including retinoic acid (RA), play a major role in the maintenance of cell populations in the adult pancreas. Pancreatic ductal adenocarcinomas (PDACs) contain lower amounts of VA and express lower levels of retinoic acid receptors (RARs) compared to normal human pancreatic tissues. Our goal was to determine if VA signaling directly impacts molecular events underlying pancreatic carcinogenesis using cell-type specific genetic approaches in mice. We knocked out retinoic acid receptor beta (RAR-β) selectively in pancreatic cells by tamoxifen treatment after crossing these adult RAR-β

Indexed as

cellular proliferationPancreatic cancerretinoic acid receptorsvitamin A

Identifiers

PMID39949931
PMCPMC11815370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.